- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03023202
UWCCC Molecular Tumor Board Registry
June 13, 2023 updated by: University of Wisconsin, Madison
UWCCC Precision Medicine Molecular Tumor Board Registry
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
5000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cancer Connect
- Phone Number: 8006228922
- Email: clinicaltrials@cancer.wisc.edu
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin Carbone Cancer Center
-
Principal Investigator:
- Mark Burkard, PhD
-
Contact:
- Cancer Connect
- Phone Number: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This study will include all patients age ≥18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.
It will require each patient to have the ability to understand and willingness to sign a written informed consent document.
Description
Inclusion Criteria:
- Clinically suspected or histologically confirmed solid or hematological malignancy
- Undergoing genetic testing of tumor
- Ability to understand written informed consent document
- Willingness to sign written informed consent document
Exclusion Criteria:
- Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PMMTB
This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures. |
PMMTB is a clinical intervention, NOT a research intervention.
The research component of this study is to observe the outcomes of the PMMTB.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of acceptance of molecular tumor board recommendations
Time Frame: Up to 5 years
|
How often the molecular tumor board's recommendations are accepted
|
Up to 5 years
|
Benefit from PMMTB recommended treatment
Time Frame: Up to 5 years
|
Whether patients benefit from PMMTB recommended treatment
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of mutations with protein overexpression
Time Frame: Up to 5 years
|
Correlate mutations identified in tumor tissue with protein overexpression
|
Up to 5 years
|
Correlations of mutations with circulating tumor DNA
Time Frame: Up to 5 years
|
Correlate mutations identified in tumor tissue with circulating tumor DNA
|
Up to 5 years
|
Correlations of mutations with spheroid culture investigations
Time Frame: Up to 5 years
|
Correlate mutations identified in tumor tissue with spheroid culture investigations
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Burkard, MD, PhD, University of Wisconsin, Madison
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2016
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2027
Study Registration Dates
First Submitted
January 13, 2017
First Submitted That Met QC Criteria
January 13, 2017
First Posted (Estimated)
January 18, 2017
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 13, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW15068
- P30CA014520 (U.S. NIH Grant/Contract)
- 2015-1370 (Other Identifier: Institutional Review Board)
- A533400 (Other Identifier: UW Madison)
- SMPH\UWCCC\GENERAL (Other Identifier: UW Madison)
- NCI-2019-06343 (Registry Identifier: NCI Trial ID)
- 1R37CA226526-01A1 (U.S. NIH Grant/Contract)
- Protocol Version 11/22/2021 (Other Identifier: UW Madison)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Neoplasms
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
-
Duke UniversityActive, not recruitingHematologic MalignancyUnited States
-
St. Petersburg State Pavlov Medical UniversityCompleted
Clinical Trials on PMMTB (Precision Medicine Molecular Tumor Board)
-
Jill M KolesarEli Lilly and CompanyRecruitingNon-Small Cell Lung CancerUnited States
-
Beijing Tiantan HospitalBeijing GeneX Health Technology Co., LtdRecruitingRecurrent High Grade GliomaChina
-
Tianjin Medical University Second HospitalUnknown
-
University Hospital, AkershusRecruiting
-
Dartmouth-Hitchcock Medical CenterRecruiting
-
Rady Pediatric Genomics & Systems Medicine InstituteEnrolling by invitation
-
Rady Pediatric Genomics & Systems Medicine InstituteRecruiting
-
Supernus Pharmaceuticals, Inc.CompletedSialorrheaUnited States, Ukraine, Russian Federation
-
City Hospital No 40, Saint Petersburg, RussiaWithdrawnCoronary Heart Disease (CHD)